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Background
The advent of highly active antiretroviral therapies
(HAART) changed the course of human immunodefi-
ciency virus (HIV) infection. However, HAART induces a
large range of toxicities, highlighting the need for novel
therapeutic strategies, such as an effective therapeutic vac-
cine. Vaccines act via dendritic cells (DCs), which induce,
regulate and maintain immune responses.
Methods
In our view, three parameters are critical for the genera-
tion of potent ex vivo-generated DC vaccines for HIV
patients: 1) antigen; 2) DC type; and 3) activation signal.
With this in mind, we designed a clinical trial (IRB#008-
017; BB-IND #13748) to test the safety and immune effi-
cacy of a therapeutic HIV vaccine consisting of autologous
DCs generated ex vivo from monocytes cultured with GM-
CSF/IFN-alpha and loaded with five lipidated HIV anti-
gens (LIPO5). Our trial exploits a combination of: 1) HIV-
derived lipopeptides that cover nef, gag and pol epitopes
– binding to >90% of HLA molecules and permitting pres-
entation of T cell epitopes and generation of humoral
immunity; 2) Interferon (IFN)-DCs, which demonstrate
powerful priming functions in vitro; and 3) LPS activation,
which enhances priming by IFN-DCs. Such a vaccine is
expected to induce strong and diverse HIV-specific
immune responses.
Results
This phase I clinical trial in 19 asymptomatic HIV-infected
patients with undetectable viral load while treated with
HAART will test the safety of DC vaccination and of ana-
lytical treatment interruption (ATI). Patients receive four
monthly DC vaccinations in conjunction with antiretrovi-
ral therapy. Twelve weeks after the fourth vaccine, patients
who meet the pre-specified criteria will stop HAART. ATI
will last for up to six months.
Conclusion
The primary end point of the trial is safety. Secondary end-
points are immune, including: strength of HIV-specific
CD4/CD8 responses, proportion of responders, and
breadth of T cell responses. Immune responses will be
assessed using IFN-gamma ELISPOT, polychromatic flow
cytometry, EPIMAX and transcriptional profiling.
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